BiotechTube

ABBV-6628 + SYFOVRE

Phase 1/2Recruiting
0 watching 0 views this week⚡ Active
41
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Geographic Atrophy

Conditions

Geographic Atrophy, Age-Related Macular Degeneration

Trial Timeline

Aug 13, 2025 → Oct 1, 2029

NCT ID
NCT07160179

About ABBV-6628 + SYFOVRE

ABBV-6628 + SYFOVRE is a phase 1/2 stage product being developed by AbbVie for Geographic Atrophy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07160179. Target conditions include Geographic Atrophy, Age-Related Macular Degeneration.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT07160179Phase 1/2Recruiting

Competing Products

20 competing products in Geographic Atrophy

See all competitors
ProductCompanyStageHype Score
avacincaptad pegolAstellas PharmaPhase 3
77
Avacincaptad PegolAstellas PharmaPhase 2/3
65
avacincaptad pegolAstellas PharmaApproved
85
Avacincaptad pegol (ACP)Astellas PharmaPre-clinical
23
Avacincaptad Pegol + ShamAstellas PharmaPhase 3
77
FWY003 + PlaceboNovartisPhase 2
52
CLG561 + LFG316 + Sham injectionNovartisPhase 2
52
LFG316 + Sham + LFG316 Lower doseNovartisPhase 2
52
LampalizumabRochePhase 3
77
LampalizumabRochePhase 3
77
LampalizumabRochePhase 3
77
RO7669330 + Syfovre™ + Izervay™RochePhase 1
33
RO7303359RochePhase 1
33
SAR446597 + Sham ComparatorSanofiPhase 1/2
40
PozelimabRegeneron PharmaceuticalsPhase 1
32
IONIS-FB-Lrx + Placebo (sterline saline 0.9%)Ionis PharmaceuticalsPhase 2
49
Tinlarebant + PlaceboBelite BioPhase 3
74
PegcetacoplanApellis PharmaceuticalsPre-clinical
18
APL-2 + APL-2Apellis PharmaceuticalsPhase 3
72
APL-2, PegcetacoplanApellis PharmaceuticalsPhase 3
72

Other Products from AbbVie

Pancrelipase + PancrelipaseApproved
85
CREONApproved
85
Venetoclax + AzacitidineApproved
85
Oxybutynin + PlaceboApproved
85
Glecaprevir-pibrentasvirApproved
85